Alembic Pharma has announced its third quarter results. Pranav Amin, director of Alembic Pharma says, the revenues have gone up 15%, YoY. He further says, the company so far has filed 41 abbreviated new drug applications (ANDAs). “Over the next couple of years, we should see quite a bit of growth coming in international generic,” he adds.
first published: Feb 9, 2012 02:16 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty slips below 24,800 as breadth weakens; SMIDs underperform | Closing Bell
Live: Nifty eyes broader market volatility, FOMC outcome for next cues | Opening Bell
Live: Nifty recovers 100 pts from day's lows in a choppy session; smallcaps shine | Closing Bell
Live: Can Nifty reclaim 26,000 after RS 7.5 lakh crore selloff? | IndiGo in focus | Opening Bell
